Johanna Friedl-Naderer Sells $25.4K of Dyne Therapeutics Inc (DYN) — SEC Form 4, Sep 08, 2026
Open-Market Net Sale · SEC Form 4
−$25,408
10b5-1 Plan
Equity position changed by -0.7%
Equity Position
153K sh
153,982 → 152,897
Equity Change
-0.7%
shares held after vs before
Filing Lag
0 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Johanna Friedl-Naderer CIK 0001915598 |
Officer
|
Johanna Friedl-Naderer at Dyne Therapeutics Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
$43,380
More from this insider at Dyne Therapeutics Inc
| 2026-08-17 | Sell | -$5,939 | View |
| 2026-06-17 | Sell | -$2,658 | View |
| 2026-05-14 | Sell | -$4,186 | View |
| 2026-03-06 | Sell | -$2,205 | View |
| 2026-02-17 | Award | — | View |
Non-Derivative Securities Transactions
Footnotes (5)
- F1
- Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 3, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. Show more
- F2
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $24.29 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. Show more
- F3
- Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. Show more
- F4
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.77 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. Show more
- F5
- Includes 102,966 unvested RSUs. Show more
Related filings at Dyne Therapeutics Inc
Institutional Holders
13F holders · Jun 30, 2026
247
institutional managers reporting a position
Largest by reported value
- T. Rowe Price Investment Management, Inc. $687M
- Black Rock, Inc. $276M
- Jupiter Topco Llc $267M
5%+ Holders · 13D/G
4 filers
-
Fmr Llc 6.8%
-
Black Rock, Inc. 7.0%
Other insiders at Dyne Therapeutics Inc
-
Brian S Posner +$40K
-
Douglas Kerr -$116K
-
John Cox -$107K
-
Jason P Rhodes -$65.2M
GET /v1/forms/4/0001915598-26-000005
API docs
View Original SEC Filing